Mobile Wearable Devices Show Some Sleep Disturbances During Multiple Myeloma Treatment
Younger patients had a significant decrease in sleep time on days they received dexamethasone.
Multiple Myeloma
Continued Benefit Observed With Isatuximab Plus Pomalidomide and Dexamethasone in Multiple Myeloma
Adding isatuximab to pomalidomide and dexamethasone improved progression-free survival (PFS) and PFS2.
Long-Term Follow-Up Data Support Adding Daratumumab to Lenalidomide/Dexamethasone in Transplant-Ineligible MM
The median progression-free survival was not reached in the D-Rd group compared with 34.4 months in the Rd group.
Iberdomide-Based Regimens Show Promise in Relapsed/Refractory Multiple Myeloma
The median duration of response was 35.7 weeks with iberdomide, bortezomib, and dexamethasone compared with not reached in patients who received iberdomide, daratumumab, and dexamethasone or iberdomide, bortezomib, and carfilzomib
Combination Therapy Shows Promise in Patients With Ultra High-Risk Multiple Myeloma, PCL
Researchers sought to determine whether a combination therapy with bortezomib-augmented ASCT would have efficacy in patients with ultra high-risk multiple myeloma or plasma cell leukemia.
Multiple Myeloma Treatment Regimens
Find detailed drug treatment regimens for multiple myeloma, including primary therapy for both transplant candidates and non-transplant candidates.
Phase 3 Trial Evaluating Venetoclax, Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
Researchers are conducting a randomized phase 3 trial evaluating the safety and efficacy of venetoclax with azacitidine among patients with previously untreated, higher-risk MDS.
Adding Ixazomib to Dexamethasone Does Not Improve PFS Compared to Pomalidomide in Multiple Myeloma
Researchers sought to determine whether doublet therapy with dexamethasone and ixazomib would improve survival in patients with multiple myeloma compared with pomalidomide.
BCVA Changes and Ocular Symptoms May Aid Belamaf Dosing in Relapsed/Refractory Multiple Myeloma
Researchers sought to determine whether BCVA and ocular symptoms could help determine dosing for belantamab mafodotin in patients with r/r multiple myeloma.
MGTA-145 Plus Plerixafor Effective for Same-Day Hematopoietic Stem Cell Mobilization
Researchers sought to determine whether the combination of MGTA-145 and plerixafor would be effective for HSC mobilization for autologous transplant in patients with multiple myeloma.
- Loading...
Loading...
Loading... 
Loading...